Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients with Relapsed or Refractory Multiple Myeloma (MM) with Extramedullary Disease (EMD)

Principal Investigator: Hillengass, Jens

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Principal Investigator: Malek, Ehsan

A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Principal Investigator: Hassan, Hamza

Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination with Standard of Care Treatment in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Principal Investigator: Hillengass, Jens

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1…

Principal Investigator: Wang, Eunice S

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)

Principal Investigator: Malek, Ehsan

Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM)

Principal Investigator: Hillengass, Jens

A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide,…

Principal Investigator: Hillengass, Jens

Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients with Multiple Myeloma and MRD Positivity after Autologous Stem Cell Transplantation

Principal Investigator: Hillengass, Jens

Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

Principal Investigator: Ross, Maureen

Improving Host Factors in Patients with Monoclonal Gammopathies

Principal Investigator: Hillengass, Jens